Audrey Sternberg

Articles

Xevinapant Plus Standard Chemoradiotherapy Demonstrates Sustained Benefit in Locally Advanced HNSCC

September 11th 2022

The addition of xevinapant to standard-of-care chemoradiotherapy elicited continued 5-year overall survival and 3-year duration of response benefits in patients with unresected head and neck locally advanced squamous cell carcinoma.

Rucaparib Demonstrates Survival Benefits in BRCA1/2-Mutated, Relapsed Ovarian Cancer.

September 9th 2022

Rucaparib elicited a progression-free survival benefit and comparable overall survival (OS) vs chemotherapy in patients with BRCA1/2-mutated, relapsed ovarian cancer who were sensitive to platinum-based chemotherapy.

Lead-In Dosing of Sotorasib Plus Pembrolizumab Shows Promising Safety for KRAS G12C+ NSCLC

August 7th 2022

A lead-in dosing strategy for the combination of sotorasib in combination with either pembrolizumab or atezolizumab showed promising efficacy and relatively low rates of hepatotoxicity in patients with KRAS G12C–positive non–small cell lung cancer.

Lasofoxifene/Abemaciclib Shows Acceptable Safety, Promising Efficacy in Previously Treated, ESR1-Mutated Metastatic Breast Cancer

June 6th 2022

The combination of lasofoxifene and abemaciclib provided a meaningful progression-free survival benefit and elicited encouraging responses with an acceptable toxicity profile in patients with locally advanced or metastatic estrogen receptor–positive, HER2-negative breast cancer.

Ruxolitinib Plus Chemo as Pre/Postsurgical Treatment Prolongs PFS in Ovarian Cancer

June 6th 2022

Twice-daily oral ruxolitinib plus carboplatin and paclitaxel given as frontline neoadjuvant and post-surgical treatment to patients with stage III or IV ovarian cancer was found to be feasible and to improve progression-free survival compared with chemotherapy alone.

Age, Menopausal Status, and Lymph Node Involvement Among Variables Associated With Abemaciclib Discontinuation in High-Risk Early Breast Cancer

June 6th 2022

Higher treatment discontinuation rates with abemaciclib were associated with factors including age of 65 year or older, enrollment in either North America or Europe, an ECOG performance status of 1, postmenopausal status, 1 to 3 positive lymph nodes, and 4 or more preexisting comorbidities in patients with hormone receptor–positive, HER2-negative high-risk early breast cancer.

Capmatinib Plus Pembrolizumab Does Not Provide Clinical Benefit in MET Unselected, PD-L1-high Expressing NSCLC

June 6th 2022

The addition of the MET inhibitor capmatinib to pembrolizumab failed to improve clinical outcomes in patients with treatment-naïve non–small cell lung cancer with PD-L1 expression of at least 50% vs pembrolizumab alone, according to an analysis of outcomes of patients in the MET unselected population treated in a phase 2 trial.

Daratumumab and Carfilzomib Quadruplet Elicits Efficacy and Safety Benefits in High-Risk Multiple Myeloma

June 5th 2022

Induction therapy with the quadruplet regimen of daratumumab, carfilzomib, lenalidomide, and dexamethasone appears to be feasible in patients with high-risk, newly diagnosed multiple myeloma who are eligible for transplant, displaying safety benefits and responses.

Superior Survival Benefit With Ramucirumab Plus Pembrolizumab Observed in ICI-Resistant NSCLC

June 3rd 2022

The addition of ramucirumab to pembrolizumab elicited significant response among patients with advanced non–small cell lung cancer who experienced disease progression following treatment with PD-1/PD-L1 inhibitors and platinum-based doublet chemotherapy.

COVID-19 Vaccine Elicits Varied Immune Responses in cGVHD

April 27th 2022

Administration of the SARS-CoV-2 vaccine resulted in heterogeneous immune response in patients with chronic graft-vs-host disease (cGVHD), further highlighting concerns about protection against infection or severe COVID-19 disease in this population

Combination Navitoclax and Ruxolitinib Elicits Improved Bone Marrow Fibrosis in Myelofibrosis

April 12th 2022

Navitoclax plus ruxolitinib produced an improvement in bone marrow fibrosis and a reduction in variant allele frequency in patients with myelofibrosis who progressed on or had suboptimal response with prior ruxolitinib monotherapy.

T-Cell Attributes of Axi-cel Linked to Outcomes in LBCL

April 10th 2022

The T-cell attributes of axicabtagene ciloleucel impacted tumor burden, efficacy outcomes, peak levels of proinflammatory cytokines, and toxicities such as neurologic events and cytokine release syndrome in patients with relapsed/refractory large B-cell lymphoma.

Navigating Frontline RCC Treatment Paths Relies on Risk Stratification

March 16th 2022

Primo Nery Lara Jr, MD, provides an overview of the treatment landscape for patients with metastatic renal cell carcinoma.

Darolutamide Plus ADT Boosts OS in Metastatic Castration-Sensitive Prostate Cancer

February 18th 2022

The addition of darolutamide to androgen deprivation therapy and docetaxel generated better overall survival vs placebo with ADT and docetaxel in patients with metastatic castration-sensitive prostate cancer.

Adagrasib Monotherapy Elicits High Rates of Disease Control in KRAS-Mutated PDAC and Other GI Malignancies

January 21st 2022

Adagrasib monotherapy demonstrated encouraging clinical activity in patients with previously treated pancreatic ductal adenocarcinoma and other non–colorectal gastrointestinal tumors that harbor KRAS G12C mutations.

Cilta-Cel Provides Superior Option Vs Standard Regimens in Triple-Class Exposed Multiple Myeloma

December 13th 2021

Comparative data from the phase 1 CARTITUDE-1 trial and the real-world LocoMMotion study demonstrated that ciltacabtagene autoleucel bested standard options for patients with triple-class exposed multiple myeloma.

Ixazomib/Daratumumab Showcases Favorable Safety in Elderly Frail Patients With Relapsed/Refractory Myeloma

December 11th 2021

The combination of daratumumab plus ixazomib, without dexamethasone, was found to have a favorable safety profile in very elderly frail patients with relapsed or refractory multiple myeloma and high cytogenetic risk.

New Data Support Use of Palbociclib in Black and Hispanic Patients With HR+, HER2– Breast Cancer

December 8th 2021

Safety and efficacy data from a pooled pooled analysis confirm that patients who are Black or Hispanic with hormone receptor–positive, HER2-negative breast cancer can be treated with palbociclib plus endocrine therapy.

Single-Cell Spatial Analysis for Immunotherapy Response Prediction in Early TNBC Shows Promise

December 7th 2021

Imaging mass cytometry at the single-cell level showed potential as an immunotherapy response prediction tool in early triple-negative breast cancer.

Darolutamide Favorably Affects Episodic Memory Vs Enzalutamide in mCRPC

September 16th 2021

Treatment with darolutamide was associated with statistically significant benefits in episodic memory by computerized cognitive assessment compared with enzalutamide in patients with metastatic castration-resistant prostate cancer.